TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16651950

Group type: EXPERIMENTAL
Intervention: Barbed suture
Number of subjects: 188

Group type: COMPARATOR
Intervention: Conventional closure using 3-0 polydioxanone suture
Number of subjects: 188
Study: 12816290

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (ERL) using an energy level of 160 mJ/pulse and 10 Hz
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) using hand instruments
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (ERL and SRP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Statistical analysis between ERL and SRP
Number of subjects: 20
Study: 10092259

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily for 7 days
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Combined treatment and placebo groups
Number of subjects: 278
Study: 7762516

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total Body Potassium (TBK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bioelectrical Impedance Analysis (BIA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 0
Study: 2102716

Group type: COMPARATOR
Intervention: 40 mg/iv of metoclopramide (Group A)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 40 mg iv of metoclopramide and 125 mg/iv of methylprednisolone (Group B)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 2 mg/oral of lorazepam, 125 mg/iv methylprednisolone, and 1 mg/kg/oral of metoclopramide (Group C)
Number of subjects: 56
Study: 365151

Group type: EXPERIMENTAL
Intervention: Bupivacaine (Marcaine), lidocaine (Xylocaine), and epinephrine mixture
Number of subjects: 126

Group type: COMPARATOR
Intervention: Lidocaine and epinephrine
Number of subjects: 126
Study: 29462104

Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB Gold
Number of subjects: 0
Study: 27124889

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 24952938

Group type: EXPERIMENTAL
Intervention: DASS-12 (12-item Depression, Anxiety and Stress Scale)
Number of subjects: 2850

Group type: COMPARATOR
Intervention: DASS-21 (21-item Depression, Anxiety and Stress Scale)
Number of subjects: 2850
Study: 22943928

Group type: EXPERIMENTAL
Intervention: Micafungin at therapeutic dose (300 mg/body)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Micafungin at prophylactic dose (150 mg/body)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Micafungin at lower prophylactic dose (50 mg/body)
Number of subjects: 15
Study: 20823760

Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 15

Group type: COMPARATOR
Intervention: PSV
Number of subjects: 15
Study: 18436564

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control treatment (olive oil)
Number of subjects: 206
Study: 16023303

Group type: EXPERIMENTAL
Intervention: Ceftazidime continuous infusion (60 mg/kg/day following a 20 mg/kg loading dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ceftazidime intermittent administration (20 mg/kg every 8 hours)
Number of subjects: 16
Study: 14665488

Group type: EXPERIMENTAL
Intervention: Rifampin plus pyrazinamide (2RZ)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Isoniazid (6H)
Number of subjects: 76
Study: 10348466

Group type: EXPERIMENTAL
Intervention: L-dopa/carbidopa (750 mg per day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: L-selegiline (10 mg per day)
Number of subjects: 16
Study: 8611072

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma (FFP) 2 U
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 2157983

Group type: EXPERIMENTAL
Intervention: Aerosolized amiloride (5 mmol per liter; 3.5 ml four times daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Aerosolized amiloride
Number of subjects: 14
Study: 7241678

Group type: EXPERIMENTAL
Intervention: Operative techniques with no dissection or excision of the parietal vaginalis
Number of subjects: 87

Group type: COMPARATOR
Intervention: Other hydrocelectomy techniques (dissection or excision of the parietal vaginalis)
Number of subjects: 87
Study: 6368246

Group type: EXPERIMENTAL
Intervention: azimexon (3 X 600 mg) added to chemotherapy
Number of subjects: 14
Study: 31305326

Group type: EXPERIMENTAL
Intervention: Milk containing only A2 β-casein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional milk
Number of subjects: 0
Study: 28918548

Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 26745028

Group type: EXPERIMENTAL
Intervention: Women with a history of GDM and BMI <30 kg/m²
Number of subjects: 269

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 269
Study: 24647726

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral relapse prevention (RP)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 286
Study: 22552027

Group type: EXPERIMENTAL
Intervention: Red wine polyphenols
Number of subjects: 10

Group type: COMPARATOR
Intervention: De-alcoholized red wine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gin
Number of subjects: 10
Study: 20545561

Group type: EXPERIMENTAL
Intervention: Plant-based olive oil diet (PBOO; >= 3 tablespoons of olive oil/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard lower-fat diet (NCI diet; total fat > 15% and < 30%)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Plant-based olive oil diet (PBOO)
Number of subjects: 44
Study: 17613157

Group type: EXPERIMENTAL
Intervention: Resourcefulness Training (RT)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Acceptance Training (AT)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Diversional Activities (DA)
Number of subjects: 176
Study: 16040785

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 12070197

Group type: EXPERIMENTAL
Intervention: REM sleep
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NREM sleep
Number of subjects: 26
Study: 10191171

Group type: EXPERIMENTAL
Intervention: BOLD fMRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: PET
Number of subjects: 0
Study: 8649942

Group type: COMPARATOR
Intervention: Hypovolemic state (before therapy)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normovolemic state (after plasma expander)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Two-week anticoagulant treatment (dicumarol therapy)
Number of subjects: 10
Study: 2085966

Group type: EXPERIMENTAL
Intervention: TCu220C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiload 250
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nova T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 0
Study: 37868

Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31450977

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for sex classification
Number of subjects: 275056

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for age estimation
Number of subjects: 275056

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for age estimation in patients with multiple ECGs
Number of subjects: 275056

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for correlation of predicted and chronological age
Number of subjects: 275056
Study: 29029185

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus MTX
Number of subjects: 0
Study: 27652911

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 215
Study: 24873720

Group type: EXPERIMENTAL
Intervention: Davunetide (30 mg twice daily, intranasally)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 23037494

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) dissection alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 0
Study: 18468856

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17312305

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 2471

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2471
Study: 15207404

Group type: EXPERIMENTAL
Intervention: Intervention group (66 patients) with additional home care attendance provided by a lay-working person who attended a specialized course.
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (61 patients) with usual home care program of assistance.
Number of subjects: 127
Study: 10714728

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL (25 mg once per day for NYHA class II or 12.5 mg once per day for NYHA class III or IV, titrated up to 200 mg once per day)
Number of subjects: 3991

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 3991
Study: 9187478

Group type: EXPERIMENTAL
Intervention: Clonazepam (CZP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 40
Study: 23087948

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (dosage not specified, but mentions up to 10 g/day and 5 g/day as safe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (megadose therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (up to 5 g/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 0
Study: 3816292

Group type: EXPERIMENTAL
Intervention: 5 mg cimetropium bromide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mg cimetropium bromide
Number of subjects: 40
Study: 31992403

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both therapies (MAD and CPAP)
Number of subjects: 31
Study: 31397122

Group type: EXPERIMENTAL
Intervention: Thunder-fire moxibustion combined with external application of Shuangbai powder
Number of subjects: 70

Group type: COMPARATOR
Intervention: Simple thunder-fire moxibustion
Number of subjects: 70
Study: 28367845

Group type: EXPERIMENTAL
Intervention: evolocumab + standard of care (SOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard of care (SOC) alone
Number of subjects: 0
Study: 25246305

Group type: EXPERIMENTAL
Intervention: Oral dexmedetomidine 2 µg/kg (Group D1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Oral dexmedetomidine 3 µg/kg (Group D2)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Oral chloral hydrate 50 mg/kg (Group C1)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Oral chloral hydrate 100 mg/kg (Group C2)
Number of subjects: 160
Study: 23537071

Group type: EXPERIMENTAL
Intervention: VV genotype in dysglycemic patients
Number of subjects: 611
Study: 21697250

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (4,000-40,000 IU/d) plus calcium (1200 mg/d), followed by equilibration to 10,000 IU/d
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 49
Study: 18295439

Group type: EXPERIMENTAL
Intervention: Cerebral protection group (with filter)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No cerebral protection group (without filter)
Number of subjects: 35
Study: 17302076

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus clonidine, continuous infusion 10 mL x h(‐1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine plus clonidine, continuous infusion 10 mL x h(‐1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus clonidine, PCA system 5 mL every 30 minutes
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine plus clonidine, PCA system 5 mL every 30 minutes
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus clonidine, continuous infusion 5 mL h x (‐1) plus PCA 2.5 mL every 30 minutes
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine plus clonidine, continuous infusion 5 mL h x (‐1) plus PCA 2.5 mL every 30 minutes
Number of subjects: 105
Study: 12699211

Group type: EXPERIMENTAL
Intervention: Monthly physician visits
Number of subjects: 87

Group type: COMPARATOR
Intervention: Semi-annual physician visits
Number of subjects: 87

Group type: COMPARATOR
Intervention: Semiannual physician visits and monthly nurse phone calls
Number of subjects: 87
Study: 10849265

Group type: EXPERIMENTAL
Intervention: kurorinone 400 mg daily for 3 months
Number of subjects: 94

Group type: COMPARATOR
Intervention: interferon-alpha (IFN-alpha) 3 million units daily for 1 month, every other day for 2 months for 3 months
Number of subjects: 94
Study: 9213980

Group type: EXPERIMENTAL
Intervention: Suicide-preventive intervention
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study: 8256707

Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Automatic implantable cardioverter-defibrillator
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (other antiarrhythmic drug therapy)
Number of subjects: 224
Study: 3899082

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.2 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Salbutamol (0.2 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30093216

Group type: EXPERIMENTAL
Intervention: Double acquisition protocol (group 1, 50 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single acquisition protocol (group 2, 50 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Double acquisition protocol (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single acquisition protocol (group 2)
Number of subjects: 100
Study: 28612668

Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg as a single dose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antibiotics only (Control)
Number of subjects: 40
Study: 27481077

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 µg/Fluticasone 500 µg combination (SF Group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tiotropium 18 µg (T Group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (SF Group and T Group)
Number of subjects: 44
Study: 25274710

Group type: COMPARATOR
Intervention: Financial Incentive
Number of subjects: 92

Group type: COMPARATOR
Intervention: Peer Network
Number of subjects: 92

Group type: COMPARATOR
Intervention: Combined
Number of subjects: 92
Study: 23518801

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion (PE)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 34
Study: 20020282

Group type: EXPERIMENTAL
Intervention: Fenugreek seed extract
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 18996241

Group type: EXPERIMENTAL
Intervention: Therapy Assistant WREX
Number of subjects: 10
Study: 16478747

Group type: EXPERIMENTAL
Intervention: MDM2-SNP309 (T/G or G/G genotype)
Number of subjects: 153

Group type: COMPARATOR
Intervention: T/T genotype
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Comparison between T/T genotype and MDM2-SNP309 (T/G or G/G genotype)
Number of subjects: 153
Study: 14639794

Group type: EXPERIMENTAL
Intervention: Heavy soup consumers
Number of subjects: 4988

Group type: COMPARATOR
Intervention: Regular soup consumers
Number of subjects: 4988

Group type: COMPARATOR
Intervention: Occasional/non-soup consumers
Number of subjects: 4988
Study: 11143786

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study: 7802862

Group type: EXPERIMENTAL
Intervention: Clivarin 20 anti F Xa U/kg BW
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clivarin 40 anti F Xa U/kg BW
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clivarin 60 anti F Xa U/kg BW
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clivarin 80 anti F Xa U/kg BW
Number of subjects: 10
Study: 3063045

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg i.v. and a supplementary 0.025 mg/kg every second min until sleep or dysarthria, followed by paracervical blockade with 1% mepivacaine 10 ml on each side of the portio
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl 2.5 micrograms/kg and thiopentone 2 mg/kg i.v. with supplementary thiopentone 50 mg every 15 s until loss of the eyelid reflex, maintained with nitrous oxide in oxygen 2/1 and supplementary thiopentone 50 mg as required
Number of subjects: 60
Study: 31470005

Group type: EXPERIMENTAL
Intervention: Subcutaneous vedolizumab 108 mg every 2 weeks
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Intravenous vedolizumab 300 mg every 8 weeks
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Subcutaneous vedolizumab
Number of subjects: 216
Study: 29879942

Group type: EXPERIMENTAL
Intervention: HOPE SOAP©
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control soap
Number of subjects: 287
Study: 28479255

Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel applied every night before surgery
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel applied once before surgery
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel with >1 application
Number of subjects: 65
Study: 26431213

Group type: EXPERIMENTAL
Intervention: In-school asthma class
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asthma day camp
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 0
Study: 22653374

Group type: EXPERIMENTAL
Intervention: Web-based intervention (daily education about sitting correctly and video demonstrations of exercises)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 100
Study: 21212755

Group type: EXPERIMENTAL
Intervention: Atorvastatin and antioxidants (vitamins E+C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19720877

Group type: EXPERIMENTAL
Intervention: PH-797804 (N-phenyl pyridinone p38 MAP kinase inhibitor)
Number of subjects: 0
Study: 17251533

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b treatment
Number of subjects: 462

Group type: COMPARATOR
Intervention: Presence of anti‐MOG and anti‐MBP antibodies
Number of subjects: 462
Study: 15482993

Group type: EXPERIMENTAL
Intervention: Iomeprol 400 mg ml(‐1) (98 ml, injection rate 5 ml s(‐1))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Iomeprol 300 mg ml(‐1) (130 ml, injection rate 5 ml s(‐1))
Number of subjects: 50
Study: 11743591

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9757156

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 15 ng/kg body weight/min urodilatin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 22.5 ng/kg body weight/min urodilatin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8573808

Group type: EXPERIMENTAL
Intervention: Normothermic CPB (34 degrees C perfusate temperature)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hypothermic CPB (28 degrees C perfusate temperature)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (Normothermic and Hypothermic)
Number of subjects: 16
Study: 2114782

Group type: EXPERIMENTAL
Intervention: Immediate, prehospital treatment initiation with rt-PA (recombinant tissue-type plasminogen activator)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Delayed, in-hospital treatment initiation with rt-PA
Number of subjects: 190
Study: 152663

Group type: EXPERIMENTAL
Intervention: Mobilisation and manipulation
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo physiotherapy
Number of subjects: 94
Study: 31823163

Group type: EXPERIMENTAL
Intervention: Expressive writing from day 3 to day 10 of hospitalization
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no expressive writing)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 91
Study: 29283786

Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate 0.5% (Group LE)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Topical Dexamethasone 1% (Group DEX)
Number of subjects: 150
Study: 28295931

Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 192
Study: 26622431

Group type: EXPERIMENTAL
Intervention: Low-dose 90Sr-90Y therapy combined with 0.5% timolol maleate solution
Number of subjects: 72

Group type: COMPARATOR
Intervention: Physiological saline with identical dose of 90Sr-90Y
Number of subjects: 72
Study: 23537330

Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant (SCT) patients
Number of subjects: 627

Group type: COMPARATOR
Intervention: Medical (MED) or Radiation (RAD) oncology patients
Number of subjects: 627
Study: 21543962

Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 57
Study: 19530911

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 100
Study: 16923826

Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft
Number of subjects: 64

Group type: COMPARATOR
Intervention: Patellar tendon autograft
Number of subjects: 64
Study: 15327406

Group type: EXPERIMENTAL
Intervention: Serum cystatin C
Number of subjects: 85